A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects with Lupus Membranous Nephropathy (LMN) Save

Date Added
August 8th, 2017
PRO Number
Pro00068913
Researcher
James C. Oates

Silhouette
Keywords
Autoimmune disease, Lupus
Summary

The purpose of this study is to see if filgotinib and/or GS-9876 can be safe and helpful to treat patients with Lupus Membranous Nephropathy. These are both oral medications. The study will last for about one year and will involve 18 study visits. Patients will be assigned to get either filgotinib or GS-9876 at the beginning of the study. At Week 16, they will be evaluated to see if their LMN is improving. If so, they will remain on whichever drug they received. If not, they will switch to the other drug. At Week 32, patients will once again be evaluated. Based on those results, patients may remain on the same drug, or switch to the other group. This process will be blinded so that even though you will always be getting active drug, you will not know which one.

Institution
MUSC
Recruitment Contact
Margaret Lindemuth
843-792-8613
hardinm@musc.edu

A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race with Systemic Lupus Erythematosus (SLE) Save

Date Added
April 23rd, 2013
PRO Number
Pro00024258
Researcher
James C. Oates

Silhouette
Keywords
Autoimmune disease, Lupus
Summary

EMBRACE is a study of belimumab, also known as BENLYSTA, to treat lupus in adult black women and men. This study is being conducted to see if belimumab works and is safe for black patients. Patients will receive either belimumab or placebo (no drug) once a month in clinic for a year, plus their regular lupus medicines. For more information, contact Abby Powell at 843-792-0549.

Institution
MUSC
Recruitment Contact
Abby Powell
843-792-0549
powab@musc.edu

Change_preferences

-- OR --

Create_login